Globally, 64 million individuals suffer from heart failure. Over 800,000 Americans die from cardiovascular-related diseases each year, with congestive heart failure having no approved products.
The BeatBio team pursues the development of coordinated, multi-modal, multigenic therapies targeting the diverse causes of cardiovascular diseases.
Dr. Reed was the Co-Founder of Xogenex/Triple-Gene, which developed the INXN-4001 therapeutic candidate. This candidate underwent comprehensive translational studies in rats and pigs before initiating a first-in-human phase I trial with follow-up data showing functional improvement in 50% of patients after a single dose.
Founder & CEO
Dr. Thomas Reed, is the Founder of Intrexon/Precigen. During his 20+ years as Chief Science Officer of Intrexon, Dr Reed worked on numerous gene and cell therapies, including INXN-4001, a non-viral gene therapy for treating heart failure. Dr Reed retired from Intrexon in February 2020 and started BioSolution Designs with
Founder & CEO
Dr. Thomas Reed, is the Founder of Intrexon/Precigen. During his 20+ years as Chief Science Officer of Intrexon, Dr Reed worked on numerous gene and cell therapies, including INXN-4001, a non-viral gene therapy for treating heart failure. Dr Reed retired from Intrexon in February 2020 and started BioSolution Designs with the dual mission of providing advanced biotools for the global research community while simultaneously developing first-in-class therapies.
CBO
Shruti Abbato specializes in optimizing early generation cell and gene therapy approaches. Most recently, as chief business executive, Shruti led the company building and fundraising activities for cell therapy business units at SalioGen and at MaxCyte, where they focused on safer methods of gene editing and non-viral delivery. Over
CBO
Shruti Abbato specializes in optimizing early generation cell and gene therapy approaches. Most recently, as chief business executive, Shruti led the company building and fundraising activities for cell therapy business units at SalioGen and at MaxCyte, where they focused on safer methods of gene editing and non-viral delivery. Over twenty years, she has also led numerous strategy and deal processes for early-stage and publicly traded companies across therapeutic categories. Having nurtured multiple platform technologies and therapeutics through deals and company formations, Shruti brings strong deal-making capabilities and conviction for emerging therapeutics that can make step changes in patient access.
COO
Sam Glickstein brings a breadth of diverse experience to his role as Chief Operating Officer, backed by a decade-long tenure focused on operations and strategic initiatives. His distinguished career spans leadership roles within the bioindustry sector, culminating most notably in his tenure as CEO at OspreyBio. With a foundation rooted
COO
Sam Glickstein brings a breadth of diverse experience to his role as Chief Operating Officer, backed by a decade-long tenure focused on operations and strategic initiatives. His distinguished career spans leadership roles within the bioindustry sector, culminating most notably in his tenure as CEO at OspreyBio. With a foundation rooted in startup environments, Sam demonstrates proficiency in delivering impactful outcomes within constrained timelines and resource allocations.
Lead Scientific Advisor
Dr. Litsa Kranias is the Hanna Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. Dr Kranias is a world-renowned scientist whose foundational work studying the biophysical interactions between Phospholamban and SERCA2 have enabled the design of diverse therapeutic
Lead Scientific Advisor
Dr. Litsa Kranias is the Hanna Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. Dr Kranias is a world-renowned scientist whose foundational work studying the biophysical interactions between Phospholamban and SERCA2 have enabled the design of diverse therapeutic candidates. With numerous patents, over 350 peer-reviewed papers, and 40+ distinguished honors, Dr Kranias is a rare researcher who has successfully traversed the “bench to bedside” drug discovery-to-drug development path.
Open today | 09:00 am – 05:00 pm |